The Respiratory Syncytial Virus Vaccine and Monoclonal Antibody Landscape: The Road to Global Access
- Jonne Terstappen; Sarah Hak; Anant Bhan; Debby Bogaert; Louis Bont; Ursula Buchholz
Access Resources
About
This article is about the fight against respiratory syncytial virus (RSV), a major cause of illness in infants and older adults. It describes new vaccines and antibodies that are now available to protect these groups. There are 30 different treatments being tested, including protein-based, mRNA, and live-attenuated vaccines. The article highlights the importance of making these treatments available worldwide, especially in low-income countries. It also mentions the positive impact seen from using nirsevimab in high-income countries to protect infants from RSV-related health issues.
Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.